Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Injections, Intralesional”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1984

[Endoscopic preoperative intralesional injection of OK-432 in early gastric cancer].

The study group consisted of 35 patients with early gastric cancer, 16 of whom were admitted for preoperative immunotherapy. Ten to 40 K.E. of OK-432 was injected intralesionally by endoscope, and then gastrectomy was performed. After the intralesional injection, fever, nausea, vomiting and epigastralgia occurred. In cancer lesion and regional lymph node, histological findings from OK-432 treated group were compared to those of the control group. Lymphoid cell infiltration at cancer lesion was marked in OK-432 treated group, and degenerated cancer cells were found in 3 cases. On the other hand, lymphoid follicles showed a marked statistical increase in OK-432 treated group. Also the cases with marked lymphoid follicle showed increased numbers of peripheral blood lymphocyte. From the results, intralesional injection of OK-432 may confirm the tumor-associated antigenicity and serves as a useful method to potentiate the specific and/or non-specific immunity in regional lymph nodes.

Adult↗
PubMed2001

High injection pressure during intralesional injection of corticosteroids into capillary hemangiomas.

BACKGROUND: Intralesional injection of corticosteroids is an effective treatment for tumors of the head and neck. Complications are rare but include permanent loss of vision. We designed a study to investigate the mechanism for this complication. METHODS: Three fellowship-trained pediatric ophthalmologists participated in the study in a nonmasked fashion. Four patients received 5 separate treatment sessions of an intralesional injection of a 50-50 mixture of triamcinolone diacetate (40 mg/mL) and betamethasone sodium phosphate and betamethasone acetate (6 mg/mL) into capillary hemangiomas. Injection pressure was obtained in real time using a cannula designed for this purpose. Maximum pressure, mean pressure, and volume of corticosteroid were measured from each injection. RESULTS: A total of 71 injections (range, 8-33 injections per patient) was performed. The total volume of corticosteroid ranged from 0.9 to 2.1 mL. In 63 of 71 injections, the maximum pressure exceeded 100 mm Hg (range, 18.65-842.18 mm Hg). Each surgeon produced injection pressures greater than the systemic arterial pressures of each patient. CONCLUSIONS: Injection pressures exceeding the systemic arterial pressures routinely occur during intralesional injections of corticosteroids into capillary hemangiomas. Experienced surgeons participating in a nonmasked protocol were unable to prevent high injection pressures of corticosteroid. A sufficient volume of corticosteroid injected at high injection pressure would account for the embolization of corticosteroid particles into the ocular circulation from retrograde arterial flow. We recommend limiting the volume of corticosteroid and performing indirect ophthalmoscopy on all patients receiving injections of long-acting corticosteroids into the orbit and periorbital soft tissue.

Betamethasone↗
PubMed1988

Therapeutic evaluation for intralesional injection of bleomycin sulfate in 143 resistant warts.

A 1 U/ml solution of bleomycin sulfate in physiologic saline solution was injected intralesionally in 38 patients, and was compared with physiologic saline solution injection into paired warts in the same patient. No patient received more than 2 ml of bleomycin. Ninety-seven of 143 warts (67.8%) showed complete resolution after one or two bleomycin injections, while 25 warts (17.5%) showed incomplete resolution. Bleomycin local injection failed to elicit any therapeutic response in 21 warts (14.7%). The cure rate was 77% for warts on the extremities, 71.4% for periungual warts, and 47.6% for the plantar warts. The responsive warts showed hemorrhagic eschars that healed without scarring. It is concluded that this form of treatment for resistant warts, up to the dose used, is safe, reliable, and accepted by the patient.

Adolescent↗
PubMedDate not supplied

Raynaud phenomenon after treatment of verruca vulgaris of the sole with intralesional injection of bleomycin.

Intralesional injection of bleomycin (BLM) for the treatment of warts resistant to all conventional therapies is of certain interest because of the drug's low toxicity and its efficacy. However, delayed side effects may appear, particularly Raynaud phenomenon. Accordingly, some precautions must be taken in patients with vascular or collagen diseases and, as a precaution, pregnant or lactating women and infants should not be treated with this drug.

Anesthetics, Local↗
PubMed1979

Local tumor regression after intralesional injection of croton oil.

Intralesional administration of emulsified croton oil into established syngeneic transplants of murine firosarcoma no. 1023 caused complete regression of the injected tumors in C3H mice without recurrence during the period of observation. In Sewall Wright strain 2 guinea pigs, in contrast to BCG cell wall vaccine which eradicated regional lymph node metastasis as well as dermal transplants, croton oil treatment only delayed the development of metastatic disease despite the fact that the injected skin tumors did not recur. 12-O-Tetradecanoylphorbol 13-acetate (TPA), the active principle of croton oil, incorporated in mineral oil droplets in aqueous suspension, caused regression of murine tumors when injected intralesionally. Aqueous suspensions of TPA failed to eliminate the tumors. Our results suggest that tumor regression induced by croton oil of TPA emulsions was due to indiscriminate destruction of the injected tissue.

Animals↗
PubMed2006

[Clinical study on keloid treatment with intralesional injection of low concentration 5-fluorouracil].

OBJECTIVE: To explore the effect of intralesional injection of low concentration 5-fluorouracil (5-FU) on inhibition of angiogenesis of keloid. METHODS: 35 patients with 51 keloids were treated with intralesional injection of 5-FU (2-5 mg/ml) biweekly. After 3-6 times of injection, the keloids were treated with intralesional injection of corticosteroid. The average period of treatment was 10.29 months. RESULTS: The efficacy of inhibiting keloid angiogenesis by low concentration of 5-fluorouracil was 96.77%. For the patients who were treated over 6 months with both 5-FU and corticosteroid, the total efficacy was 97.14%. Among them, 45.71% of keloids achieved complete remission, 48.57% mostly remission, 2.86% partial remission and 2.86% no remission. CONCLUSION: Inhibition of keloid angiogenesis with intralesional injection of low concentration of 5-fluorouracil along with corticosteroid injection can achieve satisfactory result.

Adrenal Cortex Hormones↗
PubMed2004

Serial office-based intralesional injection of cidofovir in adult-onset recurrent respiratory papillomatosis.

Intralesional injection of cidofovir is used in the treatment of recurrent respiratory papillomatosis as an adjuvant therapy after microsurgical excision and CO2 laser therapy. This is conventionally done in the operating room with the patient under general anesthesia. We report our experience with 5 patients with adult-onset recurrent respiratory papillomatosis who were treated with intralesional injections of cidofovir after recurrence of their papillomatosis. These injections were given monthly in the office without the use of general anesthesia. Before cidofovir injection, all patients required repeated CO2 laser treatments at intervals of less than 5 months. We injected 7.5 mg/mL of cidofovir transorally into the papillomas under office telescopic control. These injections were given monthly for 3 consecutive months. The patients were then followed up for 2 to 10 months after therapy to monitor the size of the papillomas. In all 5 patients, partial remission of the laryngeal papillomatosis was noted during the follow-up period. Their need for repeat microsurgery was delayed, and their vocal function improved. Intralesional injection of cidofovir in an office setting appears to be safe and effective. It might be more convenient and cost-effective than performing the same procedure in the operating room with the patient under general anesthesia.

Adult↗
PubMed1999

The treatment of neck lymphangioma with intralesional injection of bleomycin.

We report our experience with intralesional injection of bleomycin in the treatment of neck lymphangioma. From May 1995 to April 1998, 11 patients aged between 6 to 22 months were treated with intralesional bleomycin injection. Ultrasonography and computed tomography were used to assess and select the cases suitable for sclerotherapy. Patients with lesions encasing the internal jugular vein and the carotid artery were chosen. With the patient under sedation and using ultrasound guidance, the cysts were aspirated and bleomycin was injected at a dose of 0.5 mg/kg body weight. The number of procedures varied from 1 to 4 over a period of 8 months to 1 year. Patients were initially followed-up 3 monthly, then 6 monthly and subsequently yearly. In 4 patients, the neck mass was no longer visible (excellent response). In 5 patients, the neck mass had reduced to a size (more than 50% reduction) that was cosmetically acceptable (good response). There were 2 failures (poor response). There were no complications. Our results suggest that intralesional injection of bleomycin can be effectively used to treat selected cases of neck lymphangiomas.

Antibiotics, Antineoplastic↗
PubMed1999

Pain-free intralesional injection of triamcinolone for the treatment of keloid.

Intralesional injection of triamcinolone acetonide (TA) for the treatment of keloid is painful, and lidocaine-mixed preparations are much the same. I have injected TA (10 mg/ml) at the speed of 3-6 ml/hour using an electric syringe pump 40 times for the treatment of 10 keloids, 18 times without lidocaine and 22 times with lidocaine. The 95% confidence intervals (CI) of the 100 mm visual analogue pain scale of the TA alone group and the lidocaine-mixed group were 2.0 to 9.5 mm and 1.0 to 6.7 mm respectively, suggesting that both are practically pain-free. The speed of injection is an important determinant of pain in intralesional chemotherapy. The injection should be extremely slow and lidocaine should be added for sensitive patients.

Glucocorticoids↗
PubMed2000

Management of orbital lymphangioma using intralesional injection of OK-432.

AIM: To treat orbital lymphangioma with an intralesional injection of OK-432 (group A Streptococcus pyogenes of human origin). METHOD: A 14 year old boy had a right orbital cystic lymphangioma. The visual acuity in the eye was 20/28. In an initial treatment, 0.02 mg of OK-432, was injected into the tumour after aspiration of the fluid contents, but no effect was seen. The second treatment was performed with 0.04 mg of OK-432. RESULT: 4 months later, the lesion had totally shrunk to fibrous tissue. The side effects were fever, a local inflammatory reaction lasting 3 days, and increased intraocular pressure, which was managed by draining the fluid contents. Visual acuity improved to 20/15, and the visual field defect and restriction of eye movement seen before treatment disappeared. No recurrence was noted 1 year after treatment. CONCLUSION: An intralesional injection of OK-432 shrunk the lymphangioma without functional disturbance and scar in the facial skin. OK-432 may be useful for orbital lymphangioma, but further studies are still warranted to determine efficacy, complications, and the optimal dose for safe treatment.

Adolescent↗
PubMed2001

[Treatment of hemangioma in oral and maxillofacial region with intralesional injection of pingyangmycin].

OBJECTIVE: To investigate the indication and long term treatment results of intralesional injection of Pingyangmycin for hemangiomas in oral and maxillofacial regions. METHODS: Between June 1986 and June 2000, 1040 patients with maxillofacial hemangiomas were treated by intralesional injection of Pingyangmycin PYM . There were 312 males and 712 females. The types of hemangiomas included capillary 436, cavernous 238, mixed 260, arterial venous malformation 8 and port wine stain 9 . The injection was performed in stages and multi sites, repeated after 14 to 21 days for 2 to 3 times as one course. RESULTS: All the patients were followed up for 1 to 14 years. The cure rates of capillary, mixed and cavernous hemangioma were 96.40%, 92.20% and 67.20%, respectively. No effect was found for arterial venous malformations. The best dose effect was attained in 1mg/cm(2). The best concentration of Pingyangmycin was 1mg/ml for capillary hemangioma and the concentration may be higher for cavernous hemangiomas. Fever occurred in 6.54% of the cases. Serious complications associated with Pingyangmycin injection, such as pulmonary fibrosis were not found. CONCLUSION: Intralesional injection of Pingyangmycin can be used as the therapy of choice for capillary, mixed and cavernous hemangiomas in oral and maxillofacial region. The advantages included a high cure rate, safety, short course, manipulation with ease and fewer side effects.

English Abstract↗
PubMed1986

Intralesional injections.

Several types of agents used for intradermal and intralesional injection have been presented along with general discussion of technique and principles of use. We have a great deal of respect for the effectiveness of properly utilized injections in the treatment of various conditions, and we also know that if used improperly, these agents can do more harm than good. For this reason, we caution practitioners to use common sense and to refer to product information and specific sources for additional information before using any of the medications or drugs discussed here. Special attention should be given to systemic absorption and the use of these drugs in infants and children, pregnant and nursing females, and in patients with systemic illness. Each of the agents presented must be evaluated independently and information and experience gathered will aid in the longterm results of their use. We hope this report helps to describe intralesional injections for treatment of some of the more common lesions and that your patients will benefit from this technique.

Adrenal Cortex Hormones↗
PubMed1996

Diagnosis and treatment of an ophthalmic artery occlusion during an intralesional injection of corticosteroid into an eyelid capillary hemangioma.

PURPOSE: To demonstrate the usefulness of simultaneous indirect ophthalmoscopy in the diagnosis and treatment of embolization of the ocular circulation during intralesional injection of corticosteroids into capillary hemangiomas. METHODS: A 4-month-old infant had an ophthalmic artery occlusion during an intralesional injection of corticosteroids into a right upper eyelid capillary hemangioma. The injection was discontinued immediately and a paracentesis was performed. Fluorescein angiography was performed 20 minutes and three weeks after the ophthalmic artery occlusion. RESULTS: Fluorescein angiography after the paracentesis showed delayed retinal and choroidal filling and large areas of retinal and choroidal ischemia. Three weeks after treatment, the angiographic abnormalities had resolved, and the retinal and choroidal circulations were normal. Twenty-eight months after treatment, the visual acuity was 20/20 in each eye. CONCLUSION: Ophthalmic artery occlusion can occur during intralesional injection of corticosteroids into capillary hemangiomas. Simultaneous indirect ophthalmoscopy allows the surgeon to discontinue the injection and provide treatment to allow for the best possible visual outcome after this complication.

Anti-Inflammatory Agents↗
PubMed1998

Treatment of classical Kaposi's sarcoma with intralesional injections of cidofovir: report of a case.

The effect of intralesional injections of cidofovir, a nucleotide analog with potent in vitro activity against human herpesvirus 8 (HHV-8), was studied in vivo in an HIV-negative patient with classical Kaposi's sarcoma (KS). After five weekly injections of the drug, no clinical, histological, immunohistological, or virological changes could be detected in comparison with saline-injected lesions. These findings suggest that, once the KS tumor has developed, active viral replication is no longer involved in the pathogenesis of the disease. Alternative hypotheses are that HHV-8 replication in blood-borne cells may foster growth of spindle cells in the skin, or that blocking HHV-8 may not affect existing lesions but may prevent new lesions from developing.

Aged↗
PubMed1988

Effects of intralesional injections of interferons-alpha on xenografts of human mammary carcinoma cells (BT20 and MCF-7).

The effects of intralesional injections of human natural and recombinant interferons-alpha (nIFN-alpha and rIFN-alpha A) were studied in nude mice bearing bilateral xenografts of human mammary carcinoma cells (BT 20, MCF-7). One tumor of each animal received intralesional injections, while the contralateral tumor was left undisturbed. Thus, the injected tumors were subjected to the local action of the IFNs whereas the opposite ones were exposed to the systemic effects of the IFNs seeping into the subcutaneous tissue following the intratumoral injection. When used singly these IFNs exerted an inhibitory effect on the growth of both injected and contralateral tumors, but failed to cause complete regression. Many of the cells of treated BT 20 xenografts showed significant morphological alterations (increased cell volume and nuclear pleomorphism) as compared to the untreated controls. Morphological alterations in MCF-7 tumors were difficult to assess because of the inherent pleomorphism of these cells. The immunoreactivity of BT 20 and MCF-7 tumors to monoclonal antibodies directed against milk fat globule proteins and against HLA antigens was not appreciably affected by treatment with these IFNs. This study confirms that intralesional injections of human IFNs-alpha partially inhibit the growth of human breast cancer xenografts, probably through a direct effect on the carcinoma cells. Under the present experimental conditions, the intralesional and the subcutaneous routes of administration appear to offer comparable antitumor effectiveness.

Animals↗